Advice
following an abbreviated submission
palonosetron (Aloxi®) is accepted for use within NHS Scotland.
Indication under review: prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.
A phase III double blind study demonstrated non-inferiority of palonosetron to another 5-HT3 antagonist in paediatric patients.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- palonosetron (Aloxi)
- SMC ID:
- 1073/15
- Indication:
- Prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.
- Pharmaceutical company
- Chugai Pharma UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 August 2015